MEDVi, a telehealth platform serving more than 100,000 patients, today announced an expanded physician-led program ...

Are GLP-1 drugs prescribed for weight loss becoming too outsized a line item for continued coverage through the state Medicaid program? That’s what Gov. Dan McKee’s fiscal year 2027 budget suggests.

Everyday Health independently vets all recommended products. If you purchase a featured product, we may be compensated. Learn why you can trust us. ON THIS PAGE Featured Partner While Ozempic has been ...

A lot happens in Boston every day. To help you keep up, WBUR, Boston's NPR News station, pulled these stories together just ...

In the OASIS 4 trial, oral semaglutide 25 mg taken once daily demonstrated 16.6% mean weight loss when treatment was adhered to in adult participants with obesity or overweight with one or more ...

The FDA has approved a pill form of the popular injectable obesity drug Wegovy. People on the highest dose dropped about 14 percent of their starting weight after 64 weeks, with a high number of ...

Weight loss journeys are as unique as the individuals who embark on them. We all have different body types, lifestyles, health histories and goals that shape what we need to achieve lasting results.

WASHINGTON, D.C. — In a move that could reshape how obesity and metabolic disease are treated nationwide, federal health officials unveiled a new strategy to bring high-profile GLP-1 weight-loss drugs ...

The weight-loss drug Wegovy is now being sold in pill form, an advancement that allows users to transition away from weekly injections. It's the first GLP-1 weight-loss medication to become available ...

Changes are coming in 2026 for GLP-1 drugs. Long defined by high prices, shortages and weekly injections, drugs including Wegovy and Zepbound are expected to be easier to access and afford. And new ...

In 2023, she announced that she had started using a GLP-1 weight loss medication, which she's since called "a relief" Oprah Winfrey used to believe that her weight was her "responsibility to fix." But ...